Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $10.00 target price on the medical research company’s stock.

Other analysts also recently issued research reports about the stock. HC Wainwright decreased their price objective on shares of Cytosorbents from $1.00 to $0.75 and set a “neutral” rating on the stock in a report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a report on Tuesday, October 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cytosorbents presently has an average rating of “Hold” and an average target price of $5.38.

Cytosorbents Trading Down 0.3%

NASDAQ:CTSO opened at $0.67 on Monday. The stock has a fifty day moving average price of $0.70 and a two-hundred day moving average price of $0.87. The stock has a market capitalization of $42.14 million, a price-to-earnings ratio of -3.73 and a beta of 1.32. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.71 and a current ratio of 2.11. Cytosorbents has a 1 year low of $0.60 and a 1 year high of $1.61.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Friday, January 3rd. The medical research company reported ($0.08) EPS for the quarter. Cytosorbents had a negative return on equity of 101.14% and a negative net margin of 27.77%.The company had revenue of $8.61 million for the quarter. As a group, sell-side analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Avenir Corp lifted its holdings in shares of Cytosorbents by 0.3% in the second quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after purchasing an additional 13,619 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares in the last quarter. CM Management LLC raised its position in shares of Cytosorbents by 3.1% during the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock worth $1,203,000 after purchasing an additional 38,128 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of Cytosorbents during the 3rd quarter worth approximately $161,000. Finally, GSA Capital Partners LLP purchased a new stake in Cytosorbents in the 3rd quarter valued at approximately $105,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.